NCIMMUNE LEADING EARLY CANCER DETECTION

  • ONCIMMUNE is a leading early cancer detection company

    developing and commercialising its proprietary EarlyCDT® platform technology. Oncimmune has pioneered the development of autoantibody tests that can detect cancer up to four years earlier than other methods

    Read More...


  • Lung Cancer Facts:

    Almost 80% of lung cancer is diagnosed after spread to other organs.
    The 5-year survival rate is only 18% and 56% of patients perish in the 1st year after diagnosis

    Read More


  • The 5-year survival rate for lung cancer more than triples to 55%, when found early, while still localized.

    The challenge is how to find the 12 lung cancers in a population of 1,000 high-risk patients early, before symptoms appear

    Read More


  • EarlyCDT®-Lung is a simple blood test to aid in the risk assessment and early detection of lung cancer

    in high-risk patients and those with indeterminate pulmonary nodules

    Read More...


  • Oncimmune's EarlyCDT® Technology detects autoantibodies

    part of the body's natural immune response to cancer - and can be applied to a wide range of solid tumor types

    Read More

PLEASE READ THE FOLLOWING STATEMENT CAREFULLY

Electronic versions of the materials you are seeking to access are being made available on this website by Oncimmune Holdings plc (the “Company”).

These materials are not directed to nor are they intended for access by persons located or resident in the United States, Australia, Canada, South Africa, Japan or any other jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction.

None of the securities of Company discussed or referred to in the materials you are seeking to access have been registered under the US Securities Act or 1933, as amended (the “Securities Act”) and may not be offered, sold, pledged or otherwise transferred except (1) in an offshore transaction meeting the requirements of Rule 903 or Rule 904 of Regulation S under the Securities Act, (2) pursuant to an effective registration statement under the Securities Act, or (3) pursuant to an available exemption from the registration requirements of the Securities Act, in each case in accordance with all applicable securities laws.

By clicking the “SUBMIT” button below you confirm that you (1) have read and understood the information set out above, (2) agree to be bound by its terms, (3) are not located in the United States and do not have a registered address in, and are not resident or located in, Australia, Canada, South Africa or Japan and (4) are permitted under applicable law and regulation to proceed to the following parts of this website.

Please click on the button below to confirm that you have read, understood and agree with the disclaimer above.

Yes, I accept No, I don't accept